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Abstract
Recently, activating mutations of the full length ALK receptor, with two hot spots at positions F1174 and R1275, have been
characterized in sporadic cases of neuroblastoma. Here, we report similar basal patterns of ALK phosphorylation between
the neuroblastoma IMR-32 cell line, which expresses only the wild-type receptor (ALK
WT), and the SH-SY5Y cell line, which
exhibits a heterozygous ALK F1174L mutation and expresses both ALK
WT and ALK
F1174L receptors. We demonstrate that this
lack of detectable increased phosphorylation in SH-SY5Y cells is a result of intracellular retention and proteasomal
degradation of the mutated receptor. As a consequence, in SH-SY5Y cells, plasma membrane appears strongly enriched for
ALK
WT whereas both ALK
WT and ALK
F1174L were present in intracellular compartments. We further explored ALK receptor
trafficking by investigating the effect of agonist and antagonist mAb (monoclonal antibodies) on ALK internalization and
down-regulation, either in SH-SY5Y cells or in cells expressing only ALK
WT. We observe that treatment with agonist mAbs
resulted in ALK internalization and lysosomal targeting for receptor degradation. In contrast, antagonist mAb induced ALK
internalization and recycling to the plasma membrane. Importantly, we correlate this differential trafficking of ALK in
response to mAb with the recruitment of the ubiquitin ligase Cbl and ALK ubiquitylation only after agonist stimulation. This
study provides novel insights into the mechanisms regulating ALK trafficking and degradation, showing that various ALK
receptor pools are regulated by proteasome or lysosome pathways according to their intracellular localization.
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Introduction
Full-length anaplastic lymphoma kinase (ALK) is a tyrosine
kinase receptor (RTK) originally identified in human and mouse
[1,2]. Orthologues of this receptor have also been identified in
Drosophila and Caenorabditis elegans [3,4]. In vertebrates, the ALK
receptor is expressed transiently during development of central
and peripheral nervous systems strongly suggesting implication in
development and function in this system. However ALK functions
in vertebrates remain poorly understood and in those organisms
the nature of the cognate ligand is still highly controversial [see [5]
for a review].
Deregulation of ALK signaling has been associated with
development of various cancers [see [6] for a review]. The
intracellular portion (containing the kinase domain) of ALK was
firstly identified as part of the nucleophosmin (NPM)-ALK
oncogenic fusion protein resulting from chromosomal transloca-
tion frequently associated with anaplastic large cell lymphoma
(ALCL). Other chromosomal translocations implicating intracel-
lular portion of ALK fused with different partners have been
associated with various cancers, such as EML4-ALK involved in
5% of non-small-cell lung cancer (NSCLC) [see [6] for a review].
The ALK receptor has emerged as an attractive target for the
development of anticancer therapeutic strategy [see [7] for a
review] and recently crizotinib (also known as PF-2341066) has
given hopeful results in clinical trials for the treatment of NSCLC
[8].
The full length receptor ALK has been shown to be implicated
in somatic and germinal cases of neuroblastoma through gene
amplification and/or activating point mutations [9,10,11,12,13].
Two hot spots of mutations at positions F1174 and R1275 have
been identified in sporadic cases. Using stably transfected NIH3T3
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33581cells expressing mutated ALK at position F1174 or R1275, we
recently established that the constitutive kinase of the mutated
receptors impaired their trafficking, with retention in intracellular
compartment [14]. Strikingly intracellular mislocalized receptors
were significantly less phosphorylated when compared with the
cell surface pool, and normal receptor trafficking could be restored
by abolition of its activity using the specific ALK kinase inhibitor
NVP-TAE 684 (TAE) [14]. While small molecule inhibitors are
one of the most promising strategies for the treatment of cancers
linked to RTKs, the development of monoclonal antibodies (mAb)
may also be highly valuable [15]. Moreover, combinations of
tyrosine kinase inhibitors and antibodies are already used in
therapeutic treatments [16]. We previously generated a range of
mAbs against the extracellular part of the ALK receptor and
isolated mAbs with either agonist or antagonist mAb character-
istics [17]. The full characterization of the effects of such
antibodies on the properties of the ALK receptor, including
stability and trafficking is an important prerequisite to their
potential use in clinical practice.
In this study we demonstrate that the ALK
F1174L receptor
endogenously expressed in SH-SY5Y cells is largely retained in an
intracellular compartment in a poorly phosphorylated state where
it is rapidly degraded by the proteasome. We subsequently show
that addition of agonist antibody induces ALK activation,
internalization, ubiquitylation, and lysosomal degradation of cell
surface receptor. In contrast, antagonist antibody, which dimerizes
ALK without activation, leads to internalization and plasma
membrane recycling.
Results
ALK receptor phosphorylation, localization and
degradation in neuroblastoma SH-SY5Y cells
ALK phosphorylation in SH-SY5Y and IMR-32
neuroblastoma cell lines. We first investigated the impact of
ALK mutation on receptor phosphorylation by comparing two
neuroblastoma cell lines, IMR-32 cells expressing only wild-type
receptor and SH-SY5Y cells exhibiting a heterozygous ALK
F1174L activating mutation [11,12]. As expected, in both cell
lines, a doublet at 220 kD corresponding to the full length
receptor, together with a band representing the cleaved form at
140 kD [17] were detected. The level of ALK expression in the
two cell lines was roughly similar and ALK phosphorylation was
barely discernible in either cell lines under basal conditions, even
given, the presence of an activated mutation in the SH-SY5Y cell
line (Fig. 1A). Agonist mAb stimulation performed with the mAb
46 induced an increase of ALK phosphorylation in both IMR-32
and SH-SY5Y cells (Fig. 1A, right panel: representative Western
Blot, left panel: quantification). In agreement with our previous
data [18] we observed an induction of ALK phosphorylation for
the upper band of the 220 kD doublet and the 140 kD form.
Analysis of the RNA and protein levels of ALK WT and
F1174L mutant in the SH-SY5Y neuroblastoma cell
line. Since no increase in the basal phosphorylation of the
ALK receptor could be detected in SH-SY5Y cells, we sought to
measure the relative ratio of the WT and mutant ALK receptors in
this sample. Sequencing of cDNA generated from total RNAs
Figure 1. ALK
WT and ALK
F1174L expression and phosphorylation in the SH-SY5Y neuroblastoma cell line. A. IMR-32 (WT) and SH-SY5Y
(WT/F1174L) cells were untreated or stimulated with 6 nM agonist mAb 46 for 15 min. ALK immunoprecipitates were immunoblotted with polyclonal
anti-ALK (REAB) and antiphosphotyrosine (4G10 platinium). Right panel: Quantification of the ratio P-ALK/ALK in IMR-32 and SH-SY5Y cells, results are
expressed in mean and s.e.m. B. Total RNA of IMR-32 (WT) and SH-SY5Y (WT/F1174L) were extracted and cDNA were obtained by reverse
transcription. Sequencing chromatograms of the cDNAs obtained after RT-PCR are shown. C. SH-SY5Y cells (WT/F1174L) were treated or not with the
ALK specific tyrosine kinase inhibitor NVP-TAE684 at 50 nM for two days. After ALK immunoprecipitation proteomics analysis and quantifications of
interested peptides (carrying or not the mutation spot) were done by ESI-MS, after normalization.
doi:10.1371/journal.pone.0033581.g001
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WT (Fig. 1B);
whereas in SH-SY5Y, we observed the presence of both ALK
WT
and ALK
F1174L with a ratio of 2:1 (Fig. 1B). In the parental SK-N-
SH cell line from which the SH-SY5Y cell line has been derived, a
trisomy of chromosome 2p including the ALK locus has been
observed, with two wild-type alleles for one mutated one (I.
Janoueix-Lerosey, unpublished observations). It is likely that the
SH-SY5Y cell line bears a similar 2p gain that would be consistent
with the proportion of ALK
WT and ALK
F1174L mRNAs observed
here. We next investigated the ratio of ALK
WT and ALK
F1174L
receptors for the 220 kD and 140 kD forms by mass spectrometry
in SH-SY5Y cells. After tryptic digestion and normalization using
synthetic peptides we could detect the peptide containing or not
the mutation site for both the 220 kD and the 140 kD forms
(Figures S1A and S1B). We first analyzed the 220 kD forms and
observed a ratio of more than two ALK
WT for one mutated
receptor. In contrast, the 140 kD form contained only ALK
WT
(Fig. 1C).
Kinase inhibition restored cell surface localization of the
mutated receptors in SH-SY5Y cells. We previously
demonstrated intracellular retention of activated ALK in
NIH3T3 cells stably transfected with ALK
F1174L and showed
that kinase inhibition restored maturation and cell surface
localization of the mutated receptors [14]. The lack of
ALK
F1174L in the 140 kD form in SH-SY5Y could therefore be
explained by the same intracellular trafficking defect in this cell
line, i.e. retention of ALK
F1174L in the ER/Golgi compartments.
We therefore treated SH-SY5Y cells with TAE, a small-molecule
ALK inhibitor and then performed a label-free quantitative
proteomics study of WT and F1174L mutated ALK as described
above, both for the 220 kD and 140 kD forms. TAE treatment led
to a strong increase of the amount of ALK
F1174L present in the
140 kD form, demonstrating the rescue of the normal intracellular
trafficking of the mutated receptor (Fig. 1C).
Proteasomal degradation of the intracellular pools of
ALK
WT and ALK
F1174L. In order to gain insight into the
degradation mechanisms involved in the regulation of ALK
stability, we explored the two main protein degradation pathways,
i.e. the proteasome and lysosome pathways. We took advantage of
NIH3T3 cells stably expressing only either ALK
WT (3T3/WT) or
ALK
F1174L (3T3/F1174L) and used lactacystin or bafilomycin A1
to specifically inhibit proteasome or lysosome dependent
degradation, respectively. In 3T3/WT cells, bafilomycin A1
treatment led to the enrichment of the 140 kD form of ALK
correlating with the decrease of the upper band of the 220 kD
doublet (Fig. 2A). These two products have been shown previously
to be located at the plasma membrane. The effect of bafilomycin
A1 treatment on 3T3/F1174L cells was hardy detectable. In
contrast, in both cell lines, lactacystin treatment led to an increase
of the lower band of the 220 kD doublet that was previously
shown to be an intracellular form of the receptor and an increase
in the total amount of ALK was also observed (Fig. 2A). These
results therefore indicate that the intracellular pools of ALK, either
ALK
WT or ALK
F1174L, are preferentially degraded by the
proteasome whereas the turn-over of the ALK receptor located
at the plasma membrane is achieved by lysosomes.
In SH-SY5Y cells, biotinylation experiments confirmed that the
upper band of the 220 kD doublet as well as the 140 kD form
Figure 2. Proteasome dependent degradation of receptor retained in intracellular compartment. A. NIH3T3 cells stably expressing
either the WT ALK or F1174L mutated ALK were non-treated or treated with Bafilomycin A1 (0.25 mM) or with Lactacystin (10 mM) for 16 hours. ALK
immunoprecipitates from 1 mg of total cell lysate proteins were subjected to western blot analysis. ALK was immunoblotted with polyclonal REAB
antibody. B. SH-SY5Y were non-treated or treated with Bafilomycin A1 (0.25 mM) or with Lactacystin (10 mM) for 16 hours. ALK immunoprecipitates
from 1.5 mg of total cell lysate proteins were subjected to western blot analysis using polyclonal REAB antibody. The experiment was done in
triplicates and quantified with LiCor Odyssey system. Results were expressed in percentage of control +/2 s.e.m.
doi:10.1371/journal.pone.0033581.g002
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220 kD doublet was intracellular (Figure S2). We investigated the
effect of lactacystin or bafilomycin A1 drugs on SH-SY5Y cells.
Bafilomycin A1 induced a decrease of the upper band of the
220 kD doublet correlated with an increase of the 140 kD form
and lactacysin led to a strong increase of ALK level for both the
220 kD and the 140 kD forms (Fig. 2B, left panel: representative
blot, right panel: quantification). These observations are consistent
with the results obtained in the 3T3 cells and indicate that, in this
neuroblastoma cell line, the intracellular pools of ALK, including
both ALK
WT and ALK
F1174L receptors are degraded by the
proteasome.
ALK trafficking uponagonistor antagonistmAb treatment
Agonist and antagonist mAb treatments induced ALK
internalization. We first determined whether agonist mAb
could trigger ALK internalization. The low level of ALK
expression in neuroblastoma cell lines did not allow us to follow
internalization by immunofluorescence. We thus employed
transiently transfected ALK
WT in CHO cells. To investigate the
internalization of ALK primarily located at the membrane before
treatment, we incubated living cells with agonist mAb 46 for
10 min at 4uC in order to block endocytosis. We then chased cells
at 37uC and observed the resultant, in order to allow receptor
trafficking. Using confocal microscopy we were able to detect mAb
46 bound to the ALK receptor. As expected, after incubation at
4uC we could only detect the mAb:ALK receptor complex at the
cell surface. After 159 of incubation at 37uC ALK appeared
intracellularly, and after 3 h the staining was essentially
intracellular (Fig. 3A).
Having demonstrated that agonist mAb was able to trigger ALK
internalization, we next investigated the effects of antagonist mAb
treatment. The antagonist antibodies dimerize ALK without
activation [17]. After 159 of incubation at 37uC with mAb 30,
ALK appeared intracellularly (Fig. 3B). Upon longer exposure
(3 h), the receptor was detected internally but a significant fraction
of ALK was still located at the plasma membrane in contrast with
the effect observed when employing the agonist mAb (Fig. 3B
compared to Fig. 3A).
Differential intracellular trafficking of ALK in response to
agonist or antagonist mAb. To characterize differences in
ALK trafficking in response to agonist and antagonist mAb we
further investigated the receptor intracellular trafficking after
internalization. Indeed it is well established that after ligand
induced internalization, RTK could be either addressed to
lysosome for degradation, or recycled to plasma membrane
through trafficking in specific endosomal compartments.
We first performed a co-localization study of internalized ALK
after agonist mAb 46 treatments with a marker of recycling
endosomes, transferrin. For this purpose CHO cells transiently
transfected with ALK
WT were incubated for 10 min at 4uC with
both agonist mAb 46 and transferrin-546, then cells were replaced
at 37uC for indicated times. After 15 min, 1 h and 3 h, ALK
partially co-localized with tranferrin-546 (Fig. 3A). Thus agonist
mAb treatment induced only a partial receptor recycling to plasma
membrane after internalization.
Figure 3. Agonist mAb treatment induced lysosome targeting and antagonist mAb treatment induced cell surface recyling of ALK
receptor. A. CHO cells were transiently transfected with construct encoding for ALK WT. Cells were pulsed 10 minutes on ice at 4uC with 6 nM of
agonist mAb 46 and transferrin coupled to AlexaFluor 546, then chased at 37uC in a time course manner. Direct immunodetection of agonist mAb 46
were done with anti-mouse secondary antibody coupled to Alexa Fluor 488. Cellular localization of ALK receptors were shown by
immunofluorescence using confocal laser scanning microscopy. Merge images were mounted thanks to Photoshop software. B. CHO cells were
transiently transfected with construct encoding for ALK wild type. Cells were pulsed 10 minutes on ice at 4uC with 6 nM of antagonist mAb 30 and
transferring coupled to AlexaFluor 546, then chased at 37uC in a time course manner. Direct immunodetection of antagonist mAb 30 were done with
anti-mouse secondary antibody coupled to Alexa Fluor 488. Cellular localization of ALK receptors were shown by immunofluorescence using confocal
laser scanning microscopy. Merged images were mounted thanks to photophop software. C. Experiment identical to B but with a cell pre-treatment
with monensin (50 mM) for 30 min.
doi:10.1371/journal.pone.0033581.g003
ALK Down-Regulation in Neuroblastoma
PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e33581Antagonist mAb 30 treatment led to the internalization of ALK
but an important fraction of ALK was still located at the plasma
membrane. These results could be explained by plasma membrane
recycling after internalization. Indeed internalized ALK in
response to antagonist mAb strongly co-localized with transferrin
(Fig. 3B). To fully confirm that antagonist mAb treatment induced
ALK recycling after internalization, we used monensin a classical
inhibitor of this process. Addition of 100 nM of monensin before
mAb 30 treatment led to a strong accumulation of internalized
ALK starting after 1 h of cell incubation at 37uC and ALK
strongly co-localized with transferrin-546 (compared Fig. 3B and
3C). Thus, in response to antagonist mAb treatment, ALK was
recycled to plasma membrane after internalization.
Agonist mAb treatment induced ALK degradation
whereas antagonist mAb induced ALK internalization
without down-regulation. Since both agonist and antagonist
mAb treatment induced ALK internalization in CHO, we next
investigated whether these treatments resulted in down-regulation
of the receptor in neuroblastoma cell lines. We performed cell
surface protein biotinylation experiments after exposure of the SH-
SY5Y neuroblastoma cells to agonist or antagonist mAbs.
Treatment with agonist mAb46 clearly induced a progressive
decrease of biotinylated ALK with 80% of receptor internalized
after 3 h (Fig. 4A, left panel: representative western Blot, middle
panel: quantification of cell surface ALK). Interestingly the level of
ALK decreased during mAb treatment. This effect was noticeable
after 1 h and strikingly after 3 h (Fig. 4A, right panel:
quantification of total ALK). On closer inspection the remaining
receptor largely corresponded to the intracellular ALK i.e the pool
of receptor not accessible to the mAb. Thus, ALK is internalized
and then degraded in response to agonist mAb treatment. We next
investigated the effect of antagonist mAb treatment on ALK
internalization and degradation in SH-SY5Y cells. Similarly to
experiments performed with the agonist mAb we performed cell
surface protein biotinylation experiments exposure to mAb 30
(Fig. 4B, left panel: representative Western Blot, middle panel:
quantification of cell surface ALK, right panel: quantification of
total ALK). Treatment with mAb 30 also induced a progressive
decrease of ALK biotinylation but reached a plateau with 40% of
internalization between 1 h and 3 h (Fig. 4B) correlated with a
weak decrease of total ALK. These results suggest that ALK
dimerization without activation leads to receptor internalization
followed by recycling to the plasma membrane.
Tyrosine kinase activity is required for ALK down-
regulation in neuroblastoma cell lines. We further
investigated the ALK down-regulation process induced by
agonist mAb. For this purpose, we treated IMR-32 and SH-
SY5Y with mAb 46 over a 6 h time course. We then followed
receptor activation and degradation by western blot after
immunoprecipitation. In both cell lines, agonist mAb 46 induced
ALK phosphorylation with a peak at 15 min. ALK down-
regulation led to a decrease of the receptor phosphorylation with
slower kinetics for IMR-32 cells as compared toSH-SY5Y cells
(Fig. 5A and Fig. 5B). In both cases receptor degradation started
after 1 h of agonist mAb treatment and increased with time. ,As
expected the lower 220 kD form of ALK, which corresponds to
Figure 4. Agonist mAb treatment induced ALK degradation whereas antagonist mAb induced ALK internalization without down-
regulation. A. SH-SY5Y cells were untreated (-) or treated with agonist mAb 46 for 15 min, 60 min or 3 hours. At the end of the agonist treatment,
cells were subjected to cell surface protein biotinylation. ALK immunoprecipates from 1.5 mg of total cells lysate proteins were analyzed by western
blot. Biotinalyted cell surface ALK were detected with streptavidin coupled to IRdye 800, and total ALK with REAB antibody. Experiments were done in
triplicates, total and biotinylated (cell surface) ALK were quantified with LiCor Odyssey software. Results are expressed in percentage of control +/2
s.e.m. B. SH-SY5Y cells were untreated or treated with agonist mAb 30 for 15 min, 1 h or 3 h. At the end of mAb treatment, cells were subjected to
cell surface protein biotinylation. ALK immunoprecipates from 1.5 mg of total cells lysate proteins were analyzed by western blot. Biotinalyted cell
surface ALK were detected with streptavidin coupled to IRdye 800, and total ALK with REAB antibody. Experiments were done in triplicates, total and
biotinylated (cell surface) ALK were quantified with LiCor Odyssey software. Results are expressed in percentage of control +/2 s.e.m.
doi:10.1371/journal.pone.0033581.g004
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mAb induced down-regulation.
We then investigated the importance of kinase activity in the
degradation of ALK. As expected, pretreatment with the inhibitor
TAE led to a strong inhibition of ALK phosphorylation induced
by mAb46 treatment (Fig. 5C, upper panel: representative
Western Blot, lower panel: quantification). Interestingly, TAE
treatment strongly inhibited the agonist induced ALK degradation
of both the 220 kD and 140 kD forms (Fig. 5C). Thus, ALK
activation is essential to trigger ALK down-regulation.
We then tested which protein degradation pathway was
involved in ALK degradation after agonist mAb stimulation.
SH-SY5Y cells were pre-treated with either lactacystin or
bafilomycin A1 for 15 min and then treated with agonist mAb
46 for 6 h. We selected this duration of treatment since it triggers
an almost complete down regulation of cell surface ALK both in
IMR-32 and SH-SY5Y cells (Fig. 5A). This treatment was much
shorter than the one used in the experiment described in Fig. 2A.
Proteasome inhibition by lactacystin had no effect on agonist
induced ALK degradation. On contrary bafilomycin A1 treatment
completely abolished ALK down-regulation after agonist treat-
ment (Fig. 5D, upper panel: representative Western Blot, lower
panel: quantification). These results demonstrated that after
agonist mAb treatment, ALK was mainly addressed to lysosome
Figure 5. ALK down-regulation after agonist mAb 46 treatment. A. IMR-32 (WT) and B. SH-SY5Y (WT/F1174L) were treated with mAb
46 for 15 min to 6 h. ALK immunoprecipitates from 1.5 mg of total cell lysate proteins were submitted to western blot. Total ALK were
immunoblotted with polyclonal REAB and phosphorylated ALK were detected with monoclonal phosphotyrosine antibody 4G10 platinium. Tubulin
acted as a loading control. C. SH-SY5Y cells were pre-treated or not with 50 nM NVP-TAE684 one hour before cell stimulation by agonist mAb 46 at
6 nM in time course manner (0 min to 6 h). ALK immunoprecipitates from 1.5 mg of total cell lysate proteins were submitted to western-blot analysis
and immunoblotted as described. Lower panel: Experiments were done in triplicates and the 220 kD forms (the doublet was impossible to separate)
and the 140 kD form of ALK were quantified with LiCor Odyssey software. Results are expressed in percentage of control +/2 s.e.m. D. SH-SY5Y cells
were pre-treated with either bafilomycin (0.25 mM) or lactacystin (10 mM) for 159, then non treated or treated with agonist mAb 46 at 6 nM during
6 hours. ALK immunoprecipitates from 1.5 mg of total cell lysate proteins were submitted to Western-blot analysis as described. Lower panel:
Experiments were done in triplicates total ALK (220 kD forms+140 kD form) was quantified with LiCor Odyssey software. Results are expressed in
percentage of control +/2 s.e.m.
doi:10.1371/journal.pone.0033581.g005
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membrane.
ALK activation is required for Cbl recruitment and
receptor ubiquitylation. Ubiquitylation of RTK has been
demonstrated to be a critical event in the regulation of intracellular
sorting and lysosome targeting [19] and the ALK receptor has
been previously showed to recruit the ubiquitin ligase Cbl after
activation [20]. We therefore investigated whether differential
ALK intracellular trafficking in response to mAb is related to the
recruitment of Cbl and receptor ubiquitylation.
We first performed Cbl immunoprecipitation, examining co-
immunoprecipitation of ALK by immunoblotting in SH-SY5Y
cells. In control conditions we could not detect ALK co-
immunoprecipitation with Cbl. Agonist mAb treatment led to
co-immunoprecipitation of Cbl and ALK (Fig. 6A). Furthermore,
we also detected the phosphorylation of both proteins strongly
suggesting that the phosphorylation of Cbl resulted from ALK
activation. We then tested Cbl recruitment after ALK immuno-
precipitation. After ALK immunoprecipitation we detected a weak
recruitment of Cbl in control conditions; however agonist mAb
treatment strongly increased this interaction (Fig. 6B). Once again,
agonist mAb activation triggered ALK and Cbl phosphorylation.
Finally we tested ALK ubiquitylation in response to mAb
treatment in SH-SY5Y cells. For this purpose we performed
ALK immunoprecipitation after mAb treatment and investigated
ALK ubiquitylation using anti ubiquitin antibody P4D1. We
detected a basal ALK ubiquitylation, which was moderately but
significantly increased by agonist mAb 46 stimulation. Altogether
these results demonstrated that ALK activation by agonist mAb
stimulation induced receptor phosphorylation thus allowing Cbl
recruitment and receptor ubiquitylation (Fig. 6C), which is
required for lysosome targeting.
Discussion
In neuroblastoma cell lines SH-SY5Y ALK
F1174L is
intracellular and hypophosphorylated
One of the striking results of this study was the lack of
discernible difference in the ALK phosphorylation pattern in basal
conditions as well as after mAb agonist stimulation in IMR-32 cells
(ALK
WT) and SH-SY5Y cells (ALK
WT/ALK
F1174L). This result,
however, did not implicate that the mutated receptor does not
exhibit any basal constitutive activity. In Vitro kinase assay in SH-
SY5Y and IMR-32 cells confirmed higher kinase activity of the
ALK
F1174L compared to the ALK
WT (Data not shown). We also
demonstrated that treatment with TAE684 inhibitor is able to
rescue normal trafficking of ALK
F1174L in SH-SY5Y cells, as
previously established in other models [12]. In Vitro kinase assay
and rescue of normal trafficking of the mutated receptor by kinase
inhibitor TAE, strongly suggest that lack of basal ALK
phosphorylation in SH-SY5Y cells is not reliable to a defect of
kinase activity of the mutated receptor.
Ours results on ALK phosphorylation pattern in neuroblastoma
cell line required two major comments. First, we used the general
phosphorylated tyrosine antibody 4G10 to detected ALK
phosphorylation. We could not exclude that ALK F1174L
mutation induced receptor phosphorylation on specific tyrosines
that are not recognized by the 4G10 antibody. However, detection
of ALK increased phosphorylation after agonist mAb treatment
confirmed that 4G10 is a valuable antibody to detect ALK
phosphorylation. An investigation in depth of ALK activation and
autophosphorylation mechanism induced by activating mutation
in neuroblastoma cell line appears very important to better
understand its role in neuroblastoma proliferation.
Second, our results illustrated that ALK
F1174L expression are
not necessarily link to increased ALK phosphorylation in
neuroblastomas. SH-SY5Y neuroblastoma cell lines could not be
representative to all the neuroblastoma cells bearing ALK
F1174L
mutation, and further studies of ALK phosphorylation with larger
neuroblastoma samples and neuroblastoma cell lines will be
required to confirm our results. However, comparison of ALK
phosphorylation in SH-SY5Y and IMR-32 cells shed light on
requirement to carefully investigate ALK phosphorylation in
neuroblastoma, even after activating mutation identification.
It has been suggested that ALK activation and transforming
capacity may be variable according to the mutation type. In
particular, the ALK
F1174L receptor has been shown to exhibit a
higher oncogenic potential compared to the ALK
R1275Q receptor
[21]. Interestingly, we previously demonstrated that the
ALK
R1275Q receptor was proportionally more localized at the
plasma membrane than the ALK
F1174L mutant [14]. Both the
mutation type and the expression level may therefore impact basal
phosphorylation of ALK receptor and oncogenic potential of the
mutated receptors.
Figure 6. Kinase activation dependent down-regulation was regulated by Cbl ubiquitin ligase and ALK ubiquitylation. A. SH-SY5Y
cells were treated or not with either agonist mAb 46 or antagonist mAb 30 at 6 nM during 15 or 60 min. Cbl immunoprecipitates from 2 mg total cell
lysate proteins were submitted to western-blot analysis, and then immunoblotted with polyclonal anti Cbl and ALK recruitment with polyclonal REAB
antibody. Phosphorylated ALK and Cbl were revealed with 4G10 antibody. B. SH-SY5Y cells were serum starved for 16 hours and non-treated or
treated with either agonist mAb 46 or antagonist mAb 30 at 6 nM during 15 or 60 min. ALK immunoprecipitates from 2 mg total cell lysate proteins
were submitted to western-blot analysis and then immunoblotted with polyclonal REAB. Cbl recruitment was revealed with polyclonal anti Cbl
antibody. Phosphorylated ALK and Cbl were revealed with 4G10 antibody. C. SH-SY5Y were serum starved for 16 hours, and then non-treated or
treated with either mAb 46 or mAb 30 at 6 nM for 15 minutes or 60 minutes. ALK immunoprecipitates were submitted to Western-blot analysis as
described.
doi:10.1371/journal.pone.0033581.g006
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much ALK
WT than ALK
F1174L full length ALK receptor at
220 kD. Furthermore our analysis showed that the form at 140 kD
did not contain any ALK
F1174L indicating that the full length form
of the mutated receptor essentially did not reach the membrane.
Thus the truncated form at 140 kD appears to be a valuable
marker of normal receptor trafficking. The mutated receptor was
essentially retained in intracellular compartments with very low
level of basal phosphorylation in agreement with previous data
obtained in other cell systems [14]. Importantly, ALK inhibition
by TAE684 restored normal trafficking of mutated receptor in this
cell line as demonstrated by the detection by mass spectroscopy of
ALK
F1174L in the 140 kD form after TAE treatment. The absence
of detectable phosphorylation of the mutated ALK receptor may
rely on a permanent dephosphorylation by specific tyrosine
phosphatases. Finally, we document that intracellular pools of
ALK are degraded by the proteasome. Since kinase activation of
ALK
F1174L likely leads to its intracellular retention this phenom-
enon is particularly relevant for the mutated receptor.
ALK internalization and intracellular trafficking in
response to agonist and antagonist antibodies
In this report, we demonstrate for the first time that the full
length ALK receptor can be internalized in response to both
agonist and antagonist mAb. Indeed, it has been shown previously
that a chimeric EGFR-ALK protein composed by the extracellular
and transmembrane parts of the EGFR and the intracellular part
of ALK [21] was neither internalized nor down-regulated in
response to EGF, on contrary to the EGFR [22]. We demonstrate
that the ALK receptor, upon activation by agonist mAb, is
internalized followed by down-regulation in a lysosome dependent
degradation. In contrast, antagonist mAb treatment induces ALK
receptor internalization through addressing to recycling compart-
ments. The EGFR-ALK chimera therefore does not fully mimic
the native ALK receptor. ALK has been previously demonstrated
to be able to recruit the ubiquitin ligase Cbl after mAb agonist
stimulation [20]. We demonstrate that differences in ALK
intracellular trafficking induced by agonist or antagonist mAb is
due to the recruitment of Cbl by activated ALK, which in turn
leads to ALK ubiquitylation. In the case of the EGF receptor
endocytosis, the respective requirement of receptor dimerization,
ubiquitylation and/or kinase activation is still controversial
[23,24,25,26]. Our results on ALK internalization in response to
antagonist mAb support the hypothesis that dimerization rather
than kinase activity or ubiquitylation, is sufficient to induce
receptor internalization.
ALK degradation mechanism is dependent of receptor
subcellular localization
In this work, we establish two different mechanisms of ALK
degradation, depending on its cellular localization. The down-
regulation of the cell surface ALK receptor resulting from its
activation by agonist mAb is achieved by the lysosome. The
recruitment of the ubiquitin ligase Cbl and ALK ubiquitylation
appears to be essential regulatory events for triggering degradation
by the lysosome. In contrast, the degradation of the ALK receptor
retained in intracellular compartments relies on the proteasome.
This is true in particular for the ALK
F1174L mutant retained in the
ER/Golgi compartments as a consequence of its constitutive
activity. Intracellular retention induced by constitutive activation
has already been described for others RTK and particularly
investigated in case of the Flt3-ITD receptor [27]. A minor pool of
cell surface Flt3-ITD receptors are degraded through Cbl
dependent ubiquitylation [28], whereas intracellular Flt3-ITD
receptors are degraded by the proteasome by a largely unknown
mechanism. Our data point out the importance of deciphering the
proteasome targeting mechanism of misslocalized and constitu-
tively activated RTK. Hsp90 inhibitors and HDAC inhibitors
treatment, by stimulation of proteasome dependent degradation of
misslocalized RTK in intracellular compartment, lead to cell
proliferation inhibition [29]. Proteasome dependent degradation
of mutated ALK suggests that use of Hsp90 inhibitors or HDAC
inhibitors could be an attractive strategy to inhibit ALK dependent
neuroblastoma proliferation.
The ALK receptor is an attractive therapeutic target in several
human cancers, including neuroblastoma in which the full length
ALK molecule may be activated by point mutations. This study
provides novel insights into the mechanisms regulating sub-cellular
localization and metabolism of full length receptor and deciphers
more precisely the properties of mAbs on ALK activity and
trafficking. Interestingly, anti-ALK mAb defined as agonist
antibodies since they rapidly and transiently induced receptor
phosphorylation were shown to trigger ALK degradation when
cells were treated for several hours. We documented that ALK
activity and localization are regulated by complex mechanisms.
Further experiments will allow to determine the effects of
antibodies targeting the ALK receptor on cellular proliferation
and survival and establish whether they may be useful for a
therapeutic issue in patients affected with neuroblastoma.
Materials and Methods
Cell lines
NIH 3T3 and SH-SY5Y cells were purchased from ATCC.
IMR-32 and CHO cells were a kind gift of Dr. P. Kogner and Dr.
C. Faure respectively. The transfected 3T3/WT and 3T3/F1174L
cell lines were previously described [14]. CHO, IMR-32 and SH-
SY5Y cells were maintained respectively with F12 medium,
minimum essential medium (MEM) and F12/MEM (v/v)
supplemented with 16 non-essential amino acids and 1 mM
sodium pyruvate. Cell media were supplemented with 10% foetal
calf serum (Invitrogen, Cergy-Pontoise, France).
Antibodies and reagents
We used the following commercial antibodies were: Mouse
antiphosphotyrosine antibody 4G10 platinium (Millipore) mouse
anti-ubiquitine antibody P4D1 and rabbit anti-Cbl (Santa Cruz ,
Heidelberg, Germany)
Rabbit polyclonal anti-ALK (REAB) and monoclonal antibod-
ies anti-ALK (mAb 15, 30, 46, 48) have been previously described
[17]. The selective ALK kinase inhibitor NPV-TAE684 was
synthesized following the formula described in [30]. Lactacystin,
Bafilomycin A1, Monensin were purchased from Sigma-Aldrich,
St Quentin Fallavier, France.
Western blotting and immunoprecipitation
Cells were serum starved for 16 hours and then treated with
1 mg/ml of mAb 46, or mAb 48 and with 4 mg/ml of mAb 30.
Cells were treated with 50 nM of NVP-TAE684 for 48 h or
30 min before the addition of mAbs. Lactacystin and Bafilomycin
were used respectively at 10 mM and 0.25 mM for 16 hours in
basal conditions or 15 min in pretreatment before mAb treatment.
Cells were washed rapidly with cold phosphate buffer saline
(PBS) buffer (containing 5 mM sodium fluoride and 100 mM
sodium orthovanadate) and were lysed in a cold RIPA buffer as
described in [18]. Lysate were clarified by centrifugation at
21 000 g for 10 min at 4uC. Protein concentration was determined
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Reagent Kit (Pierce). Immunoprecipitation and Western-blot
analysis were performed as described in [14].
Biotinylation assay
Biotinlylation experiments were performed as decribed in [14]
using sulfo-NHC-LC-Biotin in PBS (Pierce). Biotinylated ALK
was detected with IRDye800CW-coupled streptavidin (1/10000,
Rockland, ME, USA), and total ALK with anti-ALK REAB and
secondary anti-rabbit IgG IRDye700DX-coupled antibodies.
Immunofluorescence
All immunofluoresence studies were performed at the Institut
du Fer a ` Moulin imaging facilities. CHO cells were transfected
with pcDNA3-ALK WT or F1174L and then cultured for two
days. Media were replaced with cold media containing 1 mg/ml of
mAb (46 or 30) and/or transferrin coupled to Alexa Fluor 546 at
50 mg/ml and placed at 4uC for 10 min. Cells were pre-treated
30 min 100 mM of Monensin prior incubation with mAb at 4uC
for 10 minutes. Cold media with ligand were removed and
replaced by hot media and cells were replaced at 37uC in a time
course manner (15–180 min). Cells were fixed with paraformal-
dehyde for 15 min at room temperature and then permeabilized
in PBS 0.5%.Triton X100 5 min. Fixation was quenched with
PBS-Glycine 0.1 M for 15 min, and then cells were blocked with
PBS-BSA 1.5% during 1 h. ALK bound mAbs were then detected
with anti-mouse IgG coupled to Alexa Fluor 488 1/400, molecular
probes) during 1 hour. After washing in PBS, cells were mounted
in Vectashield (Vector lab). Confocal laser microscopy was
performed using a TCS SP2 confocal microscope (Leica). Images
were assembled using Adobe Photoshop software.
RT-PCR and sequencing
Total RNA were extracted from SH-SY5Y or IMR-32 cells
with RNeasy extraction kit (Quiagen) according to manufactor
instruction. cDNA was synthetized from RNA by reverse
transcriptase and oligodT primer. ALK cDNA sequence compris-
ing c3353 was then amplified by PCR using Taq DNA polymerase
and the following primers
Primer F: 59ATGACTGTGTTACCGCCGGAAGC-39
Primer R: 59TTAACTGGCAAGCATGGCACAGC-39.
Presence of ALK mutation was determined by PCR products
sequencing.
Mass spectrometry analysis
a) 1D SDS-PAGE separation and Nano-LC-MS/MS Analysis
After immunoprecipitation samples were separated on a 4–12%
acrylamide SDS-PAGE gel. Proteins were visualized by coomassie
blue staining (Labsafe GEL Blue, G-Biosciences). Gel slices were
reduced, alkylated and subjected to digestion with trypsin
(Sequence Grade Modified, Roche Diagnostics) as previously
described [31].
The peptides mixtures were analyzed by nano-LC-MS/MS
using an Ultimate3000 system (Dionex S. A.) coupled to an LTQ-
Orbitrap mass spectrometer (Thermo Fisher Scientific. Bremen,
Germany). Data-dependent acquisition was performed on the
LTQ-Orbitrap mass spectrometer in the positive ion mode.
Survey MS scans were acquired in the orbitrap on the 400–
1100 m/z range with the resolution set to a value of 60 000. Each
scan was recalibrated in real time by co-injecting an internal
standard from ambient air into the C-trap (‘lock mass option’).
The 5 most intense ions per survey scan were selected for CID
fragmentation and the resulting fragments were analyzed in the
linear trap (LTQ). The parent mass list included the m/z value of
the two peptides at 497.28 Da and 514.28 Da. Target ions already
selected for MS/MS were dynamically excluded for 60 s. Data
were acquired using the Xcalibur software (version 2.0.5).
b) Database Search and Data Analysis
The resulting spectra were then analyzed via the Mascot
TM
Software created with Proteome Discoverer (version: 1.2.0.92,
Thermo Scientific) using the ‘‘homo sapiens’’ (human) non-
redundant database of the National Center for Biotechnology
Information (National Library of Medicine, Bethesda 28
th
February 2011, 235506 sequences). Carbamidomethylation of
cysteines, oxidation of methionine and protein N-terminal
acetylation were set as variable modifications for all Mascot
searches. Specificity of trypsin digestion was set for cleavage after
Lys or Arg except before Pro, and one missed trypsin cleavage site
was allowed. The mass tolerances in MS and MS/MS were set to
2 ppm and 0.8 Da respectively, and the instrument setting was
specified as ‘‘ESI-Trap.’’ All data were validated by using
myProMS (Proteomics, 2007).
c) Label-free Quantification
Quantification of peptide FNHQNIVR (wt) and LNHQNIVR
(mutant) in band 220 kD and 140 kD. To quantify the ALK
proteins (WT/F1174L), the extracted ion chromatogram (XIC)
signal of the well characterized tryptic peptide ions (wt and
mutant) was manually extracted from the MS survey of nano-LC-
MS/MS raw files using the Xcalibur software. XIC areas were
integrated in Xcalibur under the QualBrowser interface using the
ICIS algorithm. Mean values and S.D. were calculated for
quadruplicate measurements.
Supporting Information
Figure S1 (A) Shown are the MS/MS fragmentation spectra of
the tryptic peptides FNHQNIVR (wt, aa 1174–1181) and
LNHQNIVR (mutant) of Alk. (B) Signal abundance plot of the
synthetic wt and mutant peptides at different concentrations -
synthetic mutant (LNHQNIVR) black circle and synthetic wt
(FNHQNIVR) red triangle were mixed in different ratios (from
0.5 fmol to 50 fmol on column) and analyzed on a QSTAR in MS
mode. The coefficient of variation in ionization efficiency of the
wt/mutant was used to correct the relative abundance correspond
to 0.845.
(TIF)
Figure S2 Cell surface proteins of SH-SY5Y cells were
biotinalyted as described in Methods. ALK immunopre-
cipitates from 1.5 mg of total cell lysate proteins were immuno-
blotted with Strepatividine coupled to Dylight 800 for cell surface
ALK detection (in green) and total ALK were detected with
polyclonal anti-ALK (REAB) and secondary anti-rabbit IgG
coupled to IRdye700 (in red).
(TIF)
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